Key Insights

Highlights

Treatment Research

6 treatments under study, led by Cdk46 Inhibitor With Endocrine Therapy

Related Conditions

Often studied with 7 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

25.0%

1 terminated out of 4 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

0

Data Visualizations

Phase Distribution

4Total
Not Applicable (1)
Phase 2 (3)

Trial Status

Recruiting2
Terminated1
Unknown1

Clinical Trials (4)

Showing 4 of 4 trials
NCT06970912Phase 2Recruiting

ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer

NCT07366112Phase 2Recruiting

CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment

NCT05305937Not ApplicableUnknown

Implantation of CEST and CESL MRI Methods for Detection of Breast Tumors

NCT00851110Phase 2TerminatedPrimary

Adjuvant Breast Cancer Study of the Netherlands Working Party for Autotransplantation in Solid Tumors

Showing all 4 trials

Research Network

Common Treatments

  • Cdk46 Inhibitor With Endocrine Therapy1
  • Chemotherapy1
  • Dalpiciclib Aromatase Inhibitor With Ctdnaguided Therapy1
  • Mri Scan1
  • Stem Cell Reinfusion1

Active Sponsors

  • Peking University People's Hospital2
  • University Medical Center Groningen1
  • Meir Medical Center1
  • Tel Aviv University1

Top Investigators

Related Conditions

  • Earlystage Breast Cancer2
  • Ctdna Monitoring2
  • Her2negative Breast Cancer2
  • Hormone Receptorpositive Breast Cancer2
  • Malignant Tumor Of Breast1

Activity Timeline